The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid‐lowering efficacy and safety of simvastatin treatment

Our objective was to investigate the interactions between common polymorphisms in ABCB1, CYP3A4, and CYP3A5 genes and the lipid‐lowering efficacy and safety of the 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitor simvastatin.

[1]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[2]  C. Meisel,et al.  Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects , 2001, Clinical pharmacology and therapeutics.

[3]  J. Ordovás,et al.  CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia. , 2004, The American journal of cardiology.

[4]  J. Ordovás,et al.  Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. , 2004, The American journal of cardiology.

[5]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[6]  I. Hamilton-Craig,et al.  Statin‐associated myopathy , 2001, The Medical journal of Australia.

[7]  J. Xu,et al.  DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1 , 2005, Drug Metabolism and Disposition.

[8]  A. Nafziger,et al.  Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. , 2002, The American journal of medicine.

[9]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[10]  Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. , 2002, The Journal of clinical endocrinology and metabolism.

[11]  R. Böger.  Drug interactions of the statins and consequences for drug selection. , 2001, International journal of clinical pharmacology and therapeutics.

[12]  P. Joyce,et al.  A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression , 2002, The Pharmacogenomics Journal.

[13]  J. Long,et al.  An E-M algorithm and testing strategy for multiple-locus haplotypes. , 1995, American journal of human genetics.

[14]  A. Gotto,et al.  The evolving role of statins in the management of atherosclerosis. , 2000, Journal of the American College of Cardiology.

[15]  B. Tomlinson,et al.  How Well Tolerated Are Lipid-Lowering Drugs? , 2001, Drugs & aging.

[16]  E. Wang,et al.  HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein , 2001, Pharmaceutical Research.

[17]  A. Schinkel,et al.  The physiological function of drug-transporting P-glycoproteins. , 1997, Seminars in cancer biology.

[18]  T. Isenhour,et al.  Cardiovascular pharmacogenetics in the SNP era , 2003, Journal of thrombosis and haemostasis : JTH.

[19]  N. Scarpato,et al.  Polymorphisms in the Multidrug Resistance-1 (MDR1) Gene Influence the Response to Atorvastatin Treatment in a Gender-Specific Manner , 2004 .

[20]  B H Arison,et al.  In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[21]  A. Mitra,et al.  Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. , 2001, Pharmacogenomics.

[22]  A. Peyer,et al.  HMG‐CoA reductase inhibitors and P‐glycoprotein modulation , 2001, British journal of pharmacology.

[23]  T. Strandberg,et al.  Lipid-lowering response to statins is affected by CYP3A5 polymorphism. , 2004, Pharmacogenetics.

[24]  E. Schuetz,et al.  Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.

[25]  T. Sudhop,et al.  Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) , 2001, European Journal of Clinical Pharmacology.

[26]  W. Burke,et al.  Using pharmacogenetics to improve drug safety and efficacy. , 2004, JAMA.

[27]  J. Nurnberger,et al.  A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. , 1991, Nucleic acids research.

[28]  R. Lewontin,et al.  On measures of gametic disequilibrium. , 1988, Genetics.

[29]  B. Stricker,et al.  Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. , 2002, Atherosclerosis.

[30]  R. V. van Schaik,et al.  CYP3A5 variant allele frequencies in Dutch Caucasians. , 2002, Clinical chemistry.

[31]  W. März,et al.  Risk for myopathy with statin therapy in high-risk patients. , 2003, Archives of internal medicine.